About
Allmed Solutions develops, manufactures, and markets minimally invasive products designed to benefit patients by improving and shortening the recovery process. The company's products are used by physicians to treat a wide range of diseases and patients worldwide.
Allmed Solutions currently markets three minimally invasive medical device product lines: an embolic protection device, urological and biliary stents, and pelvic organ prolapse repair devices. The company is also developing a gastro-duodenal sleeve for the treatment of type 2 diabetes and a mitral valve replacement.
Each of Allmed Solutions' product lines is operated by one its subsidiaries, all of which are located in the company's corporate headquarters and benefit from its collective engineering, operating, regulatory, clinical, and marketing infrastructure to support their respective activities.
Funding history · 1 round · $3.4M total
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- When did Allmed Solutions become a publicly traded company?
- Allmed Solutions became public on the TASE in February 2007.
- What was Allmed Solutions' most recent funding round?
- Allmed Solutions completed a PIPE funding round in September 2022, raising $3.4 million. David Milch was an investor in this round.
- What significant medical achievement did Allmed Solutions' subsidiary TruLeaf Medical accomplish in December 2025?
- In December 2025, Allmed Solutions' subsidiary TruLeaf Medical achieved a landmark 'Needle-Stick' Heart Valve Replacement in a first-in-human trial.
- What was a key development for TruLeaf Medical, a subsidiary of Allmed Solutions, in September 2025?
- In September 2025, TruLeaf Medical, a subsidiary of Allmed Solutions, successfully completed stage 1 of implanting a first-of-its-kind heart valve via catheter only, without surgery.
- What grant did TruLeaf Medical, a subsidiary of Allmed Solutions, receive in August 2024?
- In August 2024, TruLeaf Medical, a subsidiary of Allmed Solutions, received an 11.5 million NIS grant from the Israel Innovation Authority.
- What was a notable development for TruLeaf Medical in February 2023?
- In February 2023, TruLeaf Medical announced plans to implant a mitral heart valve via two needle sticks only in a two-stage catheterization without surgery, aiming to potentially end open-heart surgeries.
- What significant sale did Allmed Solutions make in July 2021?
- In July 2021, Allmed Solutions sold its subsidiary Allium for 20 million NIS.
- What distribution agreement did Allium Medical sign in November 2020?
- In November 2020, Allium Medical signed a distribution agreement for its products in the United Arab Emirates and Egypt.
- What product did Allium Medical sell in August 2019?
- In August 2019, Allium Medical sold its embolic protection system for $17 million.
- What regulatory clearance did Allium Medical receive in May 2018?
- In May 2018, Allium Medical received CFDA clearance to market its minimally-invasive BPH implant and premium urological stents in China.